CASE REPORT
Developmental encephalopathy associated with a pathogenic variant in the GRIN2A gene.
More details
Hide details
1
Department of Paediatrics, Haematology and Paediatric Nephrology, Provincial Specialist Hospital, Częstochowa, Poland, Poland
2
Department of Clinical Pediatrics, School of Medicine, Collegium Medicum,
University of Warmia and Mazury in Olsztyn, Poland, Poland
3
Pediatric Neurology Department, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland, Poland
Submission date: 2025-07-17
Final revision date: 2026-06-22
Acceptance date: 2026-06-25
Online publication date: 2026-07-08
Corresponding author
Anna Bryzik Bryzik
Department of Paediatrics, Haematology and Paediatric Nephrology, Provincial Specialist Hospital, Częstochowa, Poland, Częstochowa, Poland
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Mutations in the GRIN gene family, which encode subunits of the NMDA (N-methyl-D-aspartate) receptor, have been increasingly associated with a spectrum of neurodevelopmental disorders. Among them, GRIN2A mutations play a crucial regulatory role in the receptor's function, affecting synaptic transmission and brain plasticity.
Aim:
This case study presents the clinical and genetic profile of a pediatric patient with a pathogenic GRIN2A mutation, highlighting the associated neurological phenotype, diagnostic process, and treatment approach.
Case Study:
Clinical data were collected through neurological assessments, EEG, MRI, and comprehensive genetic testing, including next-generation sequencing (NGS), with confirmation by Sanger sequencing. The patient's symptoms, including developmental delay, epileptic episodes, and behavioral abnormalities, were analyzed in the context of current literature on GRIN-related disorders
Results and Discussion:
The identified pathogenic GRIN2A mutation correlated with a neurodevelopmental phenotype characterized by early-onset epilepsy, hypotonia, and intellectual disability.
Conclusions:
The above case highlights the importance of early genetic testing in children with neurodevelopmental disorders and aphasia, as well as co-occurring epilepsy. Understanding the functional impact of specific GRIN2A mutations can guide personalized treatment strategies and contribute to a better characterization of the GRINopathy spectrum.